BR112015029144A2 - formulações de gel para guiar radioterapia - Google Patents
formulações de gel para guiar radioterapiaInfo
- Publication number
- BR112015029144A2 BR112015029144A2 BR112015029144A BR112015029144A BR112015029144A2 BR 112015029144 A2 BR112015029144 A2 BR 112015029144A2 BR 112015029144 A BR112015029144 A BR 112015029144A BR 112015029144 A BR112015029144 A BR 112015029144A BR 112015029144 A2 BR112015029144 A2 BR 112015029144A2
- Authority
- BR
- Brazil
- Prior art keywords
- radiotherapy
- gel formulations
- ray contrast
- administered
- contrast composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000001959 radiotherapy Methods 0.000 title abstract 2
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0442—Polymeric X-ray contrast-enhancing agent comprising a halogenated group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0452—Solutions, e.g. for injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0457—Semi-solid forms, ointments, gels, hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0476—Particles, beads, capsules, spheres
- A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- High Energy & Nuclear Physics (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo "formulações de gel para guiar radioterapia" a presente invenção descreve uma composição de contraste de raios x para administração local, sendo que a composição de contraste de raios x demonstra propriedades de contraste e em que ao menos 60% de uma quantidade administra-da de dita composição de contraste de raios x permanecem mais de 24 horas a 10 cm de um ponto de injeção quando a composição de contraste de raios x é adminis-trada no corpo humano ou animal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1350637 | 2013-05-24 | ||
PCT/EP2014/060673 WO2014187962A1 (en) | 2013-05-24 | 2014-05-23 | Gel formulations for guiding radiotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015029144A2 true BR112015029144A2 (pt) | 2017-07-25 |
Family
ID=50819731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015029144A BR112015029144A2 (pt) | 2013-05-24 | 2014-05-23 | formulações de gel para guiar radioterapia |
Country Status (15)
Country | Link |
---|---|
US (2) | US10561746B2 (pt) |
EP (1) | EP3003397B1 (pt) |
JP (1) | JP6537498B2 (pt) |
KR (1) | KR102242406B1 (pt) |
CN (1) | CN105407927B (pt) |
AU (1) | AU2014270358B2 (pt) |
BR (1) | BR112015029144A2 (pt) |
CA (1) | CA2913100C (pt) |
DK (1) | DK3003397T3 (pt) |
ES (1) | ES2828752T3 (pt) |
HK (1) | HK1223545A1 (pt) |
IL (1) | IL242676B (pt) |
MX (1) | MX2015016155A (pt) |
RU (1) | RU2703303C2 (pt) |
WO (1) | WO2014187962A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2703303C2 (ru) | 2013-05-24 | 2019-10-16 | Данмаркс Текниске Университет | Состав геля для лучевой терапии под визуальным контролем |
WO2016079331A1 (en) * | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for enhancing the effect of radiotherapy |
CN104645356B (zh) * | 2015-01-30 | 2018-11-13 | 复旦大学 | 一类x射线显影的热致水凝胶及其制备方法 |
US11058780B2 (en) * | 2016-05-20 | 2021-07-13 | Technical University Of Denmark | Palpable marker composition |
WO2018215595A1 (en) | 2017-05-24 | 2018-11-29 | Technical University Of Denmark | Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility |
US11124630B2 (en) * | 2017-06-04 | 2021-09-21 | Technion Research & Development Foundation Limited | Inverse-freezing compositions and use thereof |
IL257226B2 (en) * | 2018-01-29 | 2023-04-01 | Technion Res & Development Found Ltd | Compounds characterized by an inverse freezing property and their uses |
WO2019243419A1 (en) * | 2018-06-19 | 2019-12-26 | Danmarks Tekniske Universitet | Brachygel for treatment of cancer and/or for guidance of surgery |
EP3810207A1 (en) * | 2018-06-19 | 2021-04-28 | Danmarks Tekniske Universitet | Solution comprising fluorescent dye as fiducial marker |
EP3962496A4 (en) * | 2019-05-03 | 2023-01-11 | Palette Life Sciences, Inc. | IMPROVED FABRIC SPACERS |
US20220339285A1 (en) * | 2019-06-12 | 2022-10-27 | Technical University Of Denmark | Dissacharide formulations for controlled drug release |
KR102323957B1 (ko) * | 2019-07-26 | 2021-11-08 | 경북대학교 산학협력단 | 모든 자기공명영상촬영 및 전산화단층촬영 용 영상 마커 및 이의 제조 방법 |
EP4061438A4 (en) * | 2019-11-20 | 2024-01-10 | The Regents of the University of California | COMPOSITION OF LIQUID EMBOLIC MATERIAL |
CN111228215A (zh) * | 2020-03-09 | 2020-06-05 | 王岩松 | 一种自组装可成像丝素蛋白水凝胶的制备方法 |
CN111632142B (zh) * | 2020-06-24 | 2022-08-23 | 南方科技大学 | 一种基于x射线响应的药物释放系统及其制备方法和应用 |
CN112279945B (zh) * | 2020-10-13 | 2022-05-27 | 青岛科技大学 | 一种感温变色水凝胶型智能视窗及其制备方法、产品与应用 |
CN114652862A (zh) * | 2020-12-23 | 2022-06-24 | 成都纽瑞特医疗科技股份有限公司 | 一种放射性树脂微球注射剂及制备方法和用途 |
WO2022147009A1 (en) * | 2020-12-29 | 2022-07-07 | Precise-Therapeutics Llc | Compositions and associated methods for sustained-release of radioactive agents and their applications |
US11672875B2 (en) * | 2021-03-17 | 2023-06-13 | Saint Louis University | Nanoparticle-alginate gels for X-ray imaging of the vasculature |
CN115282127B (zh) * | 2022-04-21 | 2023-08-29 | 广州医科大学附属第二医院 | 壳聚糖海藻酸钙纳米粒微球及其制备方法 |
WO2023245093A1 (en) * | 2022-06-16 | 2023-12-21 | Theragenics Corporation | Photocurable compositions and methods for delivering radiation to a subject |
CN115678048B (zh) * | 2022-11-27 | 2024-05-31 | 福州大学 | 一种可促进创面愈合并减少疤痕形成的可注射复合水凝胶及其制备方法和应用 |
CN116251201B (zh) * | 2023-04-03 | 2024-04-05 | 无锡市第二人民医院 | 抗类风湿性关节炎的自组装水凝胶及其制备方法与应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE403255B (sv) | 1972-09-19 | 1978-08-07 | Pharmacia Ab | Rontgenkontrastmedel i vilket ett rontgenkontrastgivande emne utgores av en polymer i vilken ingar jodsubstituerade aromatiska grupper |
US5562099A (en) | 1990-10-05 | 1996-10-08 | Massachusetts Institute Of Technology | Polymeric microparticles containing agents for imaging |
US5514379A (en) | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
CA2222567C (en) | 1995-06-07 | 2002-01-29 | Southern Biosystems, Inc. | High viscosity liquid controlled biologically active delivery system |
DE69920425T2 (de) | 1998-04-09 | 2005-09-29 | Amersham Health As | Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter |
SE522098C2 (sv) | 2001-12-20 | 2004-01-13 | Bone Support Ab | Ett nytt benmineralsubstitut |
US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
JP3755880B2 (ja) * | 2003-06-11 | 2006-03-15 | 日本航空電子工業株式会社 | コネクタ |
US7790141B2 (en) | 2003-08-11 | 2010-09-07 | Pathak Holdings, Llc | Radio-opaque compounds, compositions containing same and methods of their synthesis and use |
EP2415484B1 (en) * | 2004-09-17 | 2014-06-18 | Durect Corporation | Sustained local anesthetic composition containing SAIB |
EP1890739A1 (en) * | 2005-05-12 | 2008-02-27 | Angiotech International Ag | Compositions and methods for treating diverticular disease |
CN101309713A (zh) * | 2005-11-17 | 2008-11-19 | 周吉尼克斯股份有限公司 | 用无针注射递送粘稠制剂 |
US20090026345A1 (en) * | 2007-07-24 | 2009-01-29 | Tracy Mark S | Electronic device shock-absorbing mounting system |
US9295736B2 (en) | 2007-09-24 | 2016-03-29 | Bar Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
US9468607B2 (en) | 2007-10-09 | 2016-10-18 | Washington University | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
EP2229147A2 (en) | 2007-12-03 | 2010-09-22 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
US8524267B2 (en) * | 2008-04-18 | 2013-09-03 | Warsaw Orthopedic, Inc. | Dexamethasone formulations in a biodegradable material |
CA3042067C (en) | 2009-12-15 | 2022-10-18 | Incept, Llc | Implants and biodegradable fiducial markers |
AU2011278308B2 (en) * | 2010-07-16 | 2014-09-04 | Technical University Of Denmark | Nanoparticle-guided radiotherapy |
US20120039814A1 (en) | 2010-08-13 | 2012-02-16 | Sample Jennifer L | Topical Compositions and Methods of Detection and Treatment |
US20120065614A1 (en) | 2010-09-10 | 2012-03-15 | University Of North Texas | Polyionic transitional metal phosphorescent complex/polymer hybrid systems for bioimaging and sensing applications |
WO2013076305A1 (en) * | 2011-11-25 | 2013-05-30 | Danmarks Tekniske Universitet | Formulation of solid nano-sized particles in a gel-forming system |
RU2703303C2 (ru) | 2013-05-24 | 2019-10-16 | Данмаркс Текниске Университет | Состав геля для лучевой терапии под визуальным контролем |
-
2014
- 2014-05-23 RU RU2015154681A patent/RU2703303C2/ru active
- 2014-05-23 AU AU2014270358A patent/AU2014270358B2/en active Active
- 2014-05-23 MX MX2015016155A patent/MX2015016155A/es unknown
- 2014-05-23 WO PCT/EP2014/060673 patent/WO2014187962A1/en active Application Filing
- 2014-05-23 CA CA2913100A patent/CA2913100C/en active Active
- 2014-05-23 CN CN201480028993.1A patent/CN105407927B/zh not_active Expired - Fee Related
- 2014-05-23 JP JP2016514435A patent/JP6537498B2/ja active Active
- 2014-05-23 BR BR112015029144A patent/BR112015029144A2/pt not_active Application Discontinuation
- 2014-05-23 EP EP14726350.3A patent/EP3003397B1/en active Active
- 2014-05-23 US US14/892,811 patent/US10561746B2/en active Active
- 2014-05-23 ES ES14726350T patent/ES2828752T3/es active Active
- 2014-05-23 KR KR1020157034426A patent/KR102242406B1/ko active IP Right Grant
- 2014-05-23 DK DK14726350.3T patent/DK3003397T3/da active
-
2015
- 2015-11-19 IL IL242676A patent/IL242676B/en active IP Right Grant
-
2016
- 2016-10-12 HK HK16111760.7A patent/HK1223545A1/zh unknown
-
2020
- 2020-01-02 US US16/732,618 patent/US20200197541A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2014270358A1 (en) | 2015-12-03 |
CN105407927A (zh) | 2016-03-16 |
CN105407927B (zh) | 2020-03-20 |
CA2913100C (en) | 2021-10-26 |
WO2014187962A1 (en) | 2014-11-27 |
CA2913100A1 (en) | 2014-11-27 |
RU2703303C2 (ru) | 2019-10-16 |
US10561746B2 (en) | 2020-02-18 |
US20200197541A1 (en) | 2020-06-25 |
DK3003397T3 (da) | 2020-11-16 |
EP3003397B1 (en) | 2020-08-19 |
JP6537498B2 (ja) | 2019-07-03 |
KR102242406B1 (ko) | 2021-04-21 |
RU2015154681A (ru) | 2017-06-30 |
HK1223545A1 (zh) | 2017-08-04 |
AU2014270358B2 (en) | 2019-01-17 |
NZ714077A (en) | 2020-12-18 |
JP2016519154A (ja) | 2016-06-30 |
MX2015016155A (es) | 2016-08-19 |
US20160089454A1 (en) | 2016-03-31 |
EP3003397A1 (en) | 2016-04-13 |
ES2828752T3 (es) | 2021-05-27 |
KR20160032008A (ko) | 2016-03-23 |
IL242676B (en) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015029144A2 (pt) | formulações de gel para guiar radioterapia | |
BR112015020302A2 (pt) | derivado de pirazol | |
BR112015021352A2 (pt) | composições antimicrobianas | |
BR112016002465A2 (pt) | terapia da combinação para o tratamento de câncer | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
BR112015022047A8 (pt) | uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina | |
BR112012021364A2 (pt) | "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas". | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
NZ749217A (en) | Androgen receptor modulator and uses thereof | |
BR112012032087A2 (pt) | composto, medicamento, e, uso de um composto | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
BR112013004889A2 (pt) | composição de proteção de superfície sem fluoropolímero | |
BR112013008601A8 (pt) | Formulações de emulsão de clevidipina contendo agentes antimicrobianos | |
BR112018014027A2 (pt) | composições e métodos para administração intravenosa de 2-bromo-1-(3,3-dinitroazeditin-1-il)etanona | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112015026238A2 (pt) | tratamento de câncer com dihidropirazino-pirazinas | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112015029987A8 (pt) | Beta-caseína a2 e a prevenção de inflamação do intestino | |
BR112015004465A2 (pt) | sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem | |
BR112016013194A2 (pt) | Composições de higiene oral compreendendo carbonato de cálcio e sílica | |
BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
BR112013028786A2 (pt) | método e composição de tratamento de sementes | |
BR112018075221A2 (pt) | micropartículas compreendendo um composto contendo enxofre | |
BR112018012765A2 (pt) | composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico. | |
BR112015032284A2 (pt) | dispositivo médico compreendendo colágeno-vi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |